Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$155.04 USD
-0.43 (-0.28%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$155.04 USD
-0.43 (-0.28%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK
by Zacks Equity Research
The going has been good for the pharma giants, which reported second-quarter results so far. Let us see what is in store for biotech bigwig GILD, VRTX and large-cap pharma company GSK.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Nike, Schlumberger, CSX and Intuitive Surgical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Nike, Schlumberger, CSX and Intuitive Surgical
BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions
by Zacks Equity Research
Two large pharma/biotech companies have reported so far, displaying strong sales trend. Let's see how Lilly (LLY) and Biogen (BIIB) are poised ahead of their scheduled results tomorrow.
Top Analyst Reports for Johnson & Johnson, Nike & Schlumberger
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Nike (NKE) and Schlumberger (SLB).
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals
by Zacks Equity Research
J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.
Dow 30 Stock Roundup: Goldman Sachs, IBM, J&J, Microsoft Earnings Impress
by Swarup Gupta
The index posted impressive gains this week, boosted by a strong economy and expectations of robust earnings.
Johnson & Johnson and General Motors: Growth and Income Stocks
by Brian Hamilton
This week I discuss two companies within the Income Investor portfolio; Johnson & Johnson (JNJ) and General Motors (GM).
Interpublic's Weber Shandwick Acquires Social Agency That Lot
by Zacks Equity Research
Interpublic's (IPG) Weber Shandwick acquires That Lot to boost its multi-platform capabilities and expand client base globally.
J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod
by Zacks Equity Research
The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.
Healthcare ETFs in Focus Following JNJ Q2 Results
by Sweta Killa
Investors should closely watch the movement of the Johnson & Johnson and keep a close eye on ETFs having double-digit allocation to this diversified drug maker.
Stock Market News For Jul 18, 2018
by Zacks Equity Research
Markets closed sharply higher on Tuesday, led by a rally in tech stocks.
J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)
by Zacks Equity Research
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
Novartis (NVS) Stock Flat Ahead of Earnings: What To Watch
by Ryan McQueeney
Shares of Novartis (NVS) added just 0.14% during regular hours Tuesday, the last day of trading before the pharma giant releases its latest quarterly earnings report. Here's what to expect tomorrow morning.
J&J's (JNJ) Phase III Study for Invokana Halted Earlier
by Zacks Equity Research
Johnson & Johnson's (JNJ) phase III CREDENCE study evaluating the efficacy and safety of its diabetes drug Invokana is being stopped early based on positive pre-specified efficacy data.
These Companies are Earnings All-Stars
by Tracey Ryniec
It's not easy to beat on earnings nearly every quarter but these 5 companies are doing just that. Can they keep up their winning streaks?
J&J's (JNJ) Q2 Earnings Beat on Higher Cancer Drug Sales
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it narrows its full year sales forecast due to currency factors.
Watch Out For Goldman
by Zacks Equity Research
Watch Out For Goldman
Stock Market News For July 17, 2018
by Zacks Equity Research
Financial stocks jumped on Monday although the broader market struggled, as impressive economic data and quarterly results failed to boost investors??? confidence.
Goldman Beats in Blankfein's Final Quarter
by Mark Vickery
Goldman Sachs (GS) CEO and Chairman Lloyd Blankfein announced his replacement this morning as the company he's run for the past 12 years easily beat earnings and revenue projections in its Q2 report.
J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised)
by Zacks Equity Research
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
J&J (JNJ) Down on Trimmed View Despite Q2 Earnings Beat
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it tightens its previously issued earnings guidance for 2018 while lowering its sales range.
Pacira Focused on Exparel Development Amid Competition
by Zacks Equity Research
Pacira (PCRX) focuses on the label expansion of its flagship product, Exparel.
Johnson & Johnson (JNJ) Slips 1.1% Ahead of Earnings: What To Watch
by Afrasiab Mian
Shares of Johnson & Johnson (JNJ) ticked down 1.1% during regular hours Monday, the last day of trading before it releases its latest quarterly earnings report. Investors displayed hesitation ahead of the report, but this is certainly still a stock to watch once the full results are in.
J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay
by Zacks Equity Research
The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.
Company News For Jul 16, 2018
by Zacks Equity Research
Companies in the news are: JNJ, T, AAPL and CSCO